In Vivo - Strategic Analysis For Medtech And Pharma Leaders since 1981

Richard Lowenthal, co-founder, and CEO of ARS Pharma, highlights the crucial unmet need for needle-free injections. Challenging issues posed by current epinephrine injectors, In Vivo questions the current and future progression of Neffy.

As the planet heats up and sea levels rise, the need to reduce carbon emissions is becoming ever more urgent. The life sciences industry is just one of many that are looking to cut the carbon it produces.

AI-powered bandages monitor wounds, deliver therapies, and detect complications, offering faster healing and personalized care for improved patient outcomes.

Tumor infiltrating lymphocyte therapies show promise for solid tumors, with a first FDA approval, but face manufacturing and access challenges as development continues.

Nonprofits are finding new ways to address market gaps and develop treatments for rare diseases with little commercial attraction.

EU medical device consultant Trevor Lewis takes note of the recent, if belated, progress towards the building of the post-MDR playing field for medical device companies in Europe, but calls political decision-makers and economic operators to account: getting it right is nothing short of a matter of life and death, he tells In Vivo.

Instead, the new study found children with more severe attention and hyperactivity issues or other mental health conditions such as anxiety were more likely to be medicated for ADHD.

Tumor infiltrating lymphocyte therapies show promise for solid tumors, with a first FDA approval, but face manufacturing and access challenges as development continues.

Nonprofits are finding new ways to address market gaps and develop treatments for rare diseases with little commercial attraction.

I am testing to see if the extra space above QF and KT boxes, and related articles have been removed.